Weber Lara Smith Buys 20,000 Shares of Fractyl Health (NASDAQ:GUTS) Stock

Fractyl Health, Inc. (NASDAQ:GUTS) CFO Weber Lara Smith purchased 20,000 shares of the business’s stock in a transaction on Monday, June 8th. The shares were purchased at an average cost of $0.69 per share, for a total transaction of $13,800.00. Following the transaction, the chief financial officer directly owned 20,000 shares of the company’s stock, valued at approximately $13,800. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Fractyl Health Trading Up 10.2%

NASDAQ GUTS opened at $0.73 on Thursday. The stock has a market capitalization of $116.10 million, a P/E ratio of -0.57 and a beta of 2.34. Fractyl Health, Inc. has a one year low of $0.38 and a one year high of $2.45. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.28 and a quick ratio of 4.28. The business has a 50 day simple moving average of $0.68 and a 200 day simple moving average of $1.08.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.23. Research analysts expect that Fractyl Health, Inc. will post -0.6 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on GUTS. Canaccord Genuity Group restated a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a report on Thursday, March 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of Fractyl Health in a research report on Tuesday, May 12th. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a report on Thursday, June 4th. Finally, Wall Street Zen raised shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Fractyl Health currently has an average rating of “Hold” and a consensus target price of $5.40.

Institutional Trading of Fractyl Health

A number of institutional investors and hedge funds have recently modified their holdings of the business. FNY Investment Advisers LLC bought a new stake in Fractyl Health during the third quarter worth $31,000. Jane Street Group LLC purchased a new stake in shares of Fractyl Health during the 2nd quarter valued at $31,000. Accredited Investors Inc. purchased a new stake in shares of Fractyl Health during the 1st quarter valued at $46,000. Scientech Research LLC bought a new stake in shares of Fractyl Health during the 3rd quarter worth $49,000. Finally, Prelude Capital Management LLC bought a new stake in shares of Fractyl Health during the 3rd quarter worth $55,000.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.